Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin in mCRPC with PTEN Loss or DNA Repair Defects
NCT02311764Phase 2Terminated
- Start
- Feb 2015
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC). Started Feb 2015; status: terminated.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02311764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311764.